Bronchiectasis Therapeutic Market Share

North American Market Forecasts

The North American region is set to dominate the bronchiectasis therapeutic market by growing at 35% during the forecast period. Due to the increasing prevalence of bronchiectasis, increased R&D activity in the field of drug development, and technological progress in the treatment of bronchiectasis, North America is expected to dominate the global market. In the United States, Bronchiectasis is a disease affecting 350,000 to 500,000 adults. With age, the risk of developing bronchiectasis is increased. Bronchiectasis is more commonly seen in women than men. There are many causes of bronchiectasis, but the cause is not known in about 40% of cases.

APAC Market Statistics

The bronchiectasis therapeutic market in the Asia Pacific is set to grow significantly during the forecast period. As bronchiectasis is a chronic condition that should be treated with lifelong therapy, it is expected to grow more rapidly during the forecast period. The overall cost of the treatment for bronchiectasis is huge, and some healthcare systems are starting to take account of this. In addition, there is an increase in the number of respiratory disorders and a growing aging population. Moreover, Japan is driving the Asia Pacific bronchiectasis therapeutic market revenue growth due to technological advances in the diagnosis and treatment of respiratory disorders as well as a dominant healthcare sector that subsequently raises regional revenues.